Type-2 Diabetes Mellitus
Conditions
Keywords
Type-2 diabetes mellitus, Add-on therapy
Brief summary
This is an open clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of an add-on therapy with DLBS3233 in improving blood glucose control, lipid profile, and adiponectin in subjects with type-2 diabetes mellitus.
Detailed description
There will only be one group in this study who will receive study treatment as follows: anti-diabetic agents currently used by respective subjects for at least 3 months prior to Screening, treatment intensification (lifestyle modification), and DLBS3233 at a dose of 100 mg once daily for 12 weeks. Clinical and laboratory examinations to evaluate the investigational drug's efficacy and safety will be performed at baseline and at interval of 6 weeks over the 12-week course of therapy.
Interventions
DRUGDLBS3233
Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
Sponsors
Dexa Medica Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male subjects with age of 40 - 70 years; or female subjects with age of 55 - 70 years (post-menopause) at screening * Diagnosed with type-2 diabetes mellitus * Have been being treated with a combination of two OHA for at least 3 months prior to screening * A1c level of \>= 7.0 % * Hemoglobin level of \>= 10 g/dL * Body Mass Index (BMI) \> 18.5 kg/m2 * Refuse insulin therapy * Able to take oral medicine
Exclusion criteria
* Subjects with symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia * Uncontrolled hypertension defined as systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg * History of or current chronic treatment with insulin * History of renal and/or liver disease * Impaired liver function: serum ALT \> 2.5 times upper limit of normal and positive result of chronic or acute hepatitis B or C test * Impaired renal function: serum creatinine \>= 1.5 times upper limit of normal * Current treatment with systemic corticosteroids or herbal (alternative) medicines * Any other disease state or uncontrolled illness, which judged by the investigator, could interfere with trial participation or trial evaluation * Participation in any other clinical studies within 30 days prior to screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of A1c level | 12 weeks | Reduction of A1c level from baseline after 12 weeks of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in HOMA-R | 6 and 12 weeks | Change in HOMA-R from baseline to every evaluation-time point |
| Change in HOMA-B | 6 and 12 weeks | Change in HOMA-B from baseline to every evaluation-time point |
| Change in adiponectin level | 6 and 12 weeks | Change in adiponectin level from baseline to every evaluation-time point |
| Change in lipid profile | 6 and 12 weeks | Change in lipid profile from baseline to every evaluation-time point, including: LDL-cholesterol (direct), HDL-cholesterol, total cholesterol, and triglycerides |
| Change in body weight | 6 and 12 weeks | Change in body weight from baseline to every evaluation-time point |
| Reduction of venous A1c level | 6 weeks | Reduction of venous A1c level from baseline to 6 weeks of treatment |
| Change in fasting insulin level | 6 and 12 weeks | Change in fasting insulin level from baseline to every evaluation-time point |
| Reduction of venous 1h-PG | 6 and 12 weeks | Reduction of venous 1 hour-post prandial plasma glucose from baseline to every evaluation-time point |
| Hematology | 6 and 12 weeks | Hematology parameters (Hemoglobin level, Hematocrit, Red Blood Cell count, White Blood Cell count as well as its differentials, and platelet count) will be evaluated at baseline, at interval of 6 weeks, and at the end of study |
| Liver function | 6 and 12 weeks | Liver function parameters (serum ALT, serum AST, gamma-glutamyl transferase, alkaline phosphatase, and total bilirubin levels) will be measured at baseline, at interval of 6 weeks, and at the end of study |
| Renal function | 6 and 12 weeks | Renal function parameter, i.e. serum creatinine level will be measured at baseline, at interval of 6 weeks, and at the end of study |
| Adverse events | 1-12 weeks | Adverse events as well as number of subjects experienced the events will be observed and evaluated during the study period (12 weeks) and until all adverse events have been recovered or stabilized. |
| Reduction of venous FPG | 6 and 12 weeks | Reduction of venous FPG from baseline to every evaluation-time point |
Countries
Indonesia
Outcome results
None listed